These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33324983)

  • 1. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.
    Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Target Oncol; 2022 May; 17(3):307-319. PubMed ID: 35460475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
    Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors.
    Adhikari A; Sapkota S; Gogia S; Kc O
    Cancer Epidemiol; 2024 Oct; 92():102639. PubMed ID: 39146874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific Response to Nivolumab in Renal Cell Carcinoma.
    Negishi T; Furubayashi N; Nakagawa T; Nishiyama N; Kitamura H; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Okajima E; Nakamura M
    Anticancer Res; 2021 Mar; 41(3):1539-1545. PubMed ID: 33788747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
    Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
    Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
    Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
    J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of survival rates in patients with metastatic renal cell carcinoma according to treatment era including cytokine and targeted therapy.
    Takagi T; Kondo T; Kennoki T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
    Jpn J Clin Oncol; 2013 Apr; 43(4):439-43. PubMed ID: 23303839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
    Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
    Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
    Saad E; Gebrael G; Semaan K; Eid M; Saliby RM; Labaki C; Sayegh N; Wells JC; Takemura K; Ernst MS; Lemelin A; Basappa NS; Wood LA; Powles T; Ernst DS; Lalani AA; Agarwal N; Xie W; Heng DYC; Choueiri TK
    Oncologist; 2024 Aug; 29(8):699-706. PubMed ID: 38630540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
    Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions.
    Ishihara H; Fukuda H; Takagi T; Kondo T; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
    Int J Urol; 2021 Jan; 28(1):99-106. PubMed ID: 33159426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
    Naito S; Kato T; Numakura K; Hatakeyama S; Koguchi T; Kandori S; Kawasaki Y; Adachi H; Kato R; Narita S; Yamamoto H; Ogawa S; Kawamura S; Obara W; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N
    Int J Clin Oncol; 2021 Oct; 26(10):1947-1954. PubMed ID: 34191191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.